secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001641172-25-022506
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes
--------------------------------------------------------------------------------

- Telomir-1 inhibited JMJD3, FBXL10, and FBXL11 histone demethylase enzymes in a Eurofins Discovery study.
- Overactivation of these enzymes silences tumor suppressors and activates pro-inflammatory and metabolic genes.
- Telomir-1 may restore normal gene expression, supporting development in cancer, autoimmune, neurodegeneration, and metabolic disorders.
- Data builds on prior results showing Telomir-1 reversed epigenetic silencing of STAT1 and TMS1 in PC3 prostate cancer xenograft models.
- Company is preparing to advance Telomir-1 into IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225022506/0001641172-25-022506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225022506/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer